Hodges Capital Management Inc. Sells 98,485 Shares of EXACT Sciences Co. (EXAS)
Hodges Capital Management Inc. reduced its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 299,885 shares of the medical research company’s stock after selling 98,485 shares during the period. EXACT Sciences comprises 1.2% of Hodges Capital Management Inc.’s investment portfolio, making the stock its 21st largest holding. Hodges Capital Management Inc.’s holdings in EXACT Sciences were worth $15,756,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. C M Bidwell & Associates Ltd. acquired a new position in EXACT Sciences during the 4th quarter worth approximately $117,000. Krilogy Financial LLC grew its holdings in EXACT Sciences by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after acquiring an additional 3,650 shares in the last quarter. Crow Point Partners LLC acquired a new position in EXACT Sciences during the 4th quarter worth approximately $145,000. Oppenheimer Asset Management Inc. grew its holdings in EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after acquiring an additional 3,072 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in EXACT Sciences during the 3rd quarter worth approximately $183,000. Institutional investors own 82.32% of the company’s stock.
Several research analysts have commented on the stock. BidaskClub upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Goldman Sachs Group assumed coverage on shares of EXACT Sciences in a report on Monday, January 29th. They set a “neutral” rating and a $51.00 price target for the company. Zacks Investment Research cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Friday, January 19th. Benchmark set a $65.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. EXACT Sciences presently has a consensus rating of “Buy” and an average price target of $52.84.
In related news, SVP D Scott Coward sold 1,665 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total transaction of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares in the company, valued at approximately $1,973,297.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kevin T. Conroy sold 110,439 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $50.49, for a total transaction of $5,576,065.11. Following the sale, the insider now owns 940,491 shares of the company’s stock, valued at approximately $47,485,390.59. The disclosure for this sale can be found here. In the last 90 days, insiders sold 662,694 shares of company stock valued at $35,934,015. Company insiders own 4.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Hodges Capital Management Inc. Sells 98,485 Shares of EXACT Sciences Co. (EXAS)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/02/08/hodges-capital-management-inc-sells-98485-shares-of-exact-sciences-co-exas.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.